Ahmedabad, March 17, 2026: Pharma companies Zydus Lifesciences Limited and Lupin Limited have signed a licensing and supply agreement to co-market an innovative Semaglutide Injection in India, aimed at treating diabetes and obesity.
Under the agreement, Zydus will manufacture the product, while Lupin will get semi-exclusive rights to co-market it in India. The drug will be sold under multiple brand names by both companies, expanding reach across the country.
The companies said the partnership will help improve access to advanced treatments for type 2 diabetes and weight management, which are rapidly growing health concerns in India. The injection comes with a patient-friendly reusable pen device designed to make treatment easier and more convenient.
This collaboration combines Zydus’ strong product development capabilities with Lupin’s wide distribution network, aiming to reach more patients and healthcare providers.
Semaglutide is a globally recognized therapy that helps control blood sugar levels and supports weight loss when combined with diet and exercise.
Zydus Lifesciences Limited (NSE: ZYDUSLIFE | BSE: 532321) shares were trading around ₹894.70, up ₹7.80 (0.88%) on March 17, 2026. The stock opened at ₹895.00, touched a high of ₹902.70, and a low of ₹890.85 during the session. The company’s market capitalization is around ₹90,030 crore.
Lupin Limited (NSE: LUPIN | BSE: 500257) shares were trading around ₹2,293.00, up ₹2.60 (0.11%) on March 17, 2026. The stock opened at ₹2,306.00, touched a high of ₹2,312.20, and a low of ₹2,285.40 during the session. The company’s market capitalization is around ₹1,05,000 crore.
